MedTrace Logo

Neurocognitive Mechanisms of Perimenstrual Estrogen Effects on Suicidality

NCT06191289 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2025-10-29

No results posted yet for this study

Summary

This within-person, crossover, 2-condition, placebo-controlled study compares the impact of two perimenstrual conditions on severity of suicidal symptoms in females with past-month suicidality but minimal risk of imminent suicide attempt. The two conditions are (1) perimenstrual administration of estradiol and (2) natural perimenstrual withdrawal from estradiol during placebo.

Conditions

  • Suicide

Interventions

DRUG

Transdermal Estradiol

1mg/24hr transdermal estradiol for 14 days starting day 7 after positive urine luteinizing hormone test Other Names: Climara

OTHER

Placebo

Weekly application of a placebo patch for 14 days starting day 7 after positive urine luteinizing hormone test

Sponsors & Collaborators

  • University of Illinois at Chicago

    lead OTHER

Principal Investigators

  • Tory A Eisenlohr-Moul, Ph.D. · University of Illinois at Chicago

  • Elizabeth Mulligan, Ph.D. · University of Illinois at Chicago

  • Katja M Schmalenberger, Ph.D. · University of Illinois at Chicago

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-16
Primary Completion
2024-12-01
Completion
2024-12-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06191289 on ClinicalTrials.gov